DOCSLIB.ORG

Case Definitions for Communicable Morbidities

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Case Definitions for Communicable Morbidities Case Definitions for Communicable Morbidities 2020 (revised September 2020) TABLE OF CONTENTS Introduction ............................................................................................................................................................... 6 Definition of Terms Used in Case Classification ................................................................................................ 7 Definition of an Epidemiologic Investigation ....................................................................................................... 7 Definition of Binational Case ................................................................................................................................. 8 Case Definitions for Communicable Morbidities Reportable in Arizona ......................................................... 9 ACUTE FLACCID MYELITIS (AFM) .................................................................................................................... 10 AMEBIASIS ......................................................................................................................................................... 13 ANAPLASMOSIS ................................................................................................................................................. 16 ANTHRAX (Bacillus anthracis) ............................................................................................................................ 19 ARBOVIRAL INFECTION .................................................................................................................................... 22 BABESIOSIS ....................................................................................................................................................... 28 BASIDIOBOLOMYCOSIS.................................................................................................................................... 32 BOTULISM .......................................................................................................................................................... 33 Botulism, Foodborne ....................................................................................................................................... 33 Botulism, Wound ............................................................................................................................................. 33 Botulism, Other ................................................................................................................................................ 34 BOTULISM, INFANT ........................................................................................................................................... 36 BRUCELLOSIS .................................................................................................................................................... 38 CAMPYLOBACTERIOSIS ................................................................................................................................... 40 CANDIDA AURIS ................................................................................................................................................. 42 CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) ....................................................................... 46 CHAGAS DISEASE AND RELATED DISEASE (American trypanosomiasis) .................................................... 52 CHANCROID (Haemophilus ducreyi) .................................................................................................................. 56 CHIKUNGUNYA .................................................................................................................................................. 58 CHLAMYDIA TRACHOMATIS INFECTION ........................................................................................................ 59 CHOLERA ........................................................................................................................................................... 61 COCCIDIOIDOMYCOSIS (Valley fever) ............................................................................................................. 63 COLORADO TICK FEVER .................................................................................................................................. 65 CONJUNCTIVITIS, ACUTE ................................................................................................................................. 66 COVID-19 (2019 NOVEL CORONAVIRUS)........................................................................................................ 68 CREUTZFELDT-JAKOB DISEASE ..................................................................................................................... 72 CRYPTOSPORIDIOSIS (Cryptosporidium parvum) ........................................................................................... 75 CYCLOSPORIASIS ............................................................................................................................................. 77 CYSTICERCOSIS ............................................................................................................................................... 78 DENGUE (Dengue, Severe dengue, Dengue-like illness) .................................................................................. 80 DIARRHEA, NAUSEA, OR VOMITING ............................................................................................................... 84 DIPHTHERIA ....................................................................................................................................................... 86 EHRLICHIOSIS ................................................................................................................................................... 89 EMERGING OR EXOTIC DISEASE .................................................................................................................... 92 ENCEPHALITIS, PARASITIC .............................................................................................................................. 94 ENCEPHALITIS, VIRAL ...................................................................................................................................... 96 ESCHERICHIA COLI, SHIGA TOXIN-PRODUCING .......................................................................................... 98 ADHS Communicable Disease Case Definitions Go to Table of Contents 2020 2 FOODBORNE DISEASE OUTBREAK .............................................................................................................. 102 GIARDIASIS ...................................................................................................................................................... 104 GLANDERS (Burkholderia mallei) ..................................................................................................................... 106 GONORRHEA ................................................................................................................................................... 107 GRANULOMATOUS AMEBIC ENCEPHALITIS (GAE), Acanthamoeba Disease excluding keratitis .............. 109 GRANULOMATOUS AMEBIC ENCEPHALITIS (GAE), Balamuthia mandrillaris Disease ............................... 111 HAEMOPHILUS INFLUENZAE, INVASIVE DISEASE ...................................................................................... 113 HANSEN’S DISEASE (Leprosy) ........................................................................................................................ 115 HANTAVIRUS INFECTION ............................................................................................................................... 117 Hantavirus Pulmonary Syndrome (HPS) ....................................................................................................... 117 Hantavirus infection, non-Hantavirus pulmonary syndrome (non-HPS) ....................................................... 117 HEMOLYTIC UREMIC SYNDROME ................................................................................................................. 120 HEPATITIS A ..................................................................................................................................................... 122 HEPATITIS B, ACUTE ....................................................................................................................................... 125 HEPATITIS B, CHRONIC .................................................................................................................................. 127 HEPATITIS B, PERINATAL ............................................................................................................................... 129 HEPATITIS C, ACUTE ...................................................................................................................................... 131 HEPATITIS C, CHRONIC .................................................................................................................................. 134 HEPATITIS C, PERINATAL............................................................................................................................... 137 HEPATITIS D ..................................................................................................................................................... 139 HEPATITIS E ....................................................................................................................................................
Load more

Recommended publications
  • Reporting of Diseases and Conditions Regulation, Amendment, M.R. 289/2014
    THE PUBLIC HEALTH ACT LOI SUR LA SANTÉ PUBLIQUE (C.C.S.M. c. P210) (c. P210 de la C.P.L.M.) Reporting of Diseases and Conditions Règlement modifiant le Règlement sur la Regulation, amendment déclaration de maladies et d'affections Regulation 289/2014 Règlement 289/2014 Registered December 23, 2014 Date d'enregistrement : le 23 décembre 2014 Manitoba Regulation 37/2009 amended Modification du R.M. 37/2009 1 The Reporting of Diseases and 1 Le présent règlement modifie le Conditions Regulation , Manitoba Règlement sur la déclaration de maladies et Regulation 37/2009, is amended by this d'affections , R.M. 37/2009. regulation. 2 Schedules A and B are replaced with 2 Les annexes A et B sont remplacées Schedules A and B to this regulation. par les annexes A et B du présent règlement. Coming into force Entrée en vigueur 3 This regulation comes into force on 3 Le présent règlement entre en vigueur January 1, 2015, or on the day it is registered le 1 er janvier 2015 ou à la date de son under The Statutes and Regulations Act , enregistrement en vertu de Loi sur les textes whichever is later. législatifs et réglementaires , si cette date est postérieure. December 19, 2014 Minister of Health/La ministre de la Santé, 19 décembre 2014 Sharon Blady 1 SCHEDULE A (Section 1) 1 The following diseases are diseases requiring contact notification in accordance with the disease-specific protocol. Common name Scientific or technical name of disease or its infectious agent Chancroid Haemophilus ducreyi Chlamydia Chlamydia trachomatis (including Lymphogranuloma venereum (LGV) serovars) Gonorrhea Neisseria gonorrhoeae HIV Human immunodeficiency virus Syphilis Treponema pallidum subspecies pallidum Tuberculosis Mycobacterium tuberculosis Mycobacterium africanum Mycobacterium canetti Mycobacterium caprae Mycobacterium microti Mycobacterium pinnipedii Mycobacterium bovis (excluding M.
    [Show full text]
  • Reportable Disease Surveillance in Virginia, 2013
    Reportable Disease Surveillance in Virginia, 2013 Marissa J. Levine, MD, MPH State Health Commissioner Report Production Team: Division of Surveillance and Investigation, Division of Disease Prevention, Division of Environmental Epidemiology, and Division of Immunization Virginia Department of Health Post Office Box 2448 Richmond, Virginia 23218 www.vdh.virginia.gov ACKNOWLEDGEMENT In addition to the employees of the work units listed below, the Office of Epidemiology would like to acknowledge the contributions of all those engaged in disease surveillance and control activities across the state throughout the year. We appreciate the commitment to public health of all epidemiology staff in local and district health departments and the Regional and Central Offices, as well as the conscientious work of nurses, environmental health specialists, infection preventionists, physicians, laboratory staff, and administrators. These persons report or manage disease surveillance data on an ongoing basis and diligently strive to control morbidity in Virginia. This report would not be possible without the efforts of all those who collect and follow up on morbidity reports. Divisions in the Virginia Department of Health Office of Epidemiology Disease Prevention Telephone: 804-864-7964 Environmental Epidemiology Telephone: 804-864-8182 Immunization Telephone: 804-864-8055 Surveillance and Investigation Telephone: 804-864-8141 TABLE OF CONTENTS INTRODUCTION Introduction ......................................................................................................................................1
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,018,158 B2 Onsoyen Et Al
    US0090181.58B2 (12) United States Patent (10) Patent No.: US 9,018,158 B2 Onsoyen et al. (45) Date of Patent: Apr. 28, 2015 (54) ALGINATE OLIGOMERS FOR USE IN 7,208,141 B2 * 4/2007 Montgomery .................. 424/45 OVERCOMING MULTIDRUG RESISTANCE 22:49 R: R388 al al W . aSOC ea. N BACTERA 7,671,102 B2 3/2010 Gaserod et al. 7,674,837 B2 3, 2010 G d et al. (75) Inventors: Edvar Onsoyen, Sandvika (NO); Rolf 7,758,856 B2 T/2010 it. Myrvold, Sandvika (NO); Arne Dessen, 7,776,839 B2 8/2010 Del Buono et al. Sandvika (NO); David Thomas, Cardiff 2006.8 R 38 8. Melist al. (GB); Timothy Rutland Walsh, Cardiff 2003/0022863 A1 1/2003 Stahlang et al. (GB) 2003/0224070 Al 12/2003 Sweazy et al. 2004/OO73964 A1 4/2004 Ellington et al. (73) Assignee: Algipharma AS, Sandvika (NO) 2004/0224922 A1 1 1/2004 King 2010.0068290 A1 3/2010 Ziegler et al. (*) Notice: Subject to any disclaimer, the term of this 2010/0305062 A1* 12/2010 Onsoyen et al. ................ 514/54 patent is extended or adjusted under 35 U.S.C. 154(b) by 184 days. FOREIGN PATENT DOCUMENTS DE 268865 A1 1, 1987 (21) Appl. No.: 13/376,164 EP O324720 A1 T, 1989 EP O 506,326 A2 9, 1992 (22) PCT Filed: Jun. 3, 2010 EP O590746 A1 4f1994 EP 1234584 A1 8, 2002 (86). PCT No.: PCT/GB2O1 O/OO1097 EP 1714660 A1 10, 2006 EP 1745705 A1 1, 2007 S371 (c)(1), FR T576 M 3/1968 (2), (4) Date: Jan.
    [Show full text]
  • Annual Report 2019 2019
    Vector-Borne Disease Section Annual Report 2019 2019 ANNUAL REPORT VECTOR-BORNE DISEASE SECTION INFECTIOUS DISEASES BRANCH DIVISION OF COMMUNICABLE DISEASE CONTROL CENTER FOR INFECTIOUS DISEASES CALIFORNIA DEPARTMENT OF PUBLIC HEALTH Gavin Newsom Governor State of California VBDS Annual Report, 2019 Contents Preface .......................................................................................................................................................................................................iii Acknowledgements ............................................................................................................................................................................ iv Suggested Citations ............................................................................................................................................................................ vi Program Overview .............................................................................................................................................................................. vii Chapters 1 Rodent-borne Diseases 1 2 Flea-borne Diseases 4 3 Tick-borne Diseases 7 4 Mosquito-borne Diseases 13 5 U.S. Forest Service Cost-Share Agreement 21 6 Vector Control Technician Certification Program 25 7 Public Information Materials and Publications 27 State of California June 2020 California Department of Public Health ii VBDS Annual Report, 2019 Preface I am pleased to present to you the 2019 Annual Report for the Vector-Borne Disease Section
    [Show full text]
  • Poster Session 2 12:00 - 14:00 Tuesday, 11Th June, 2019 Zia Ballroom Presentation Type Poster
    Poster Session 2 12:00 - 14:00 Tuesday, 11th June, 2019 Zia Ballroom Presentation type Poster 111 Molecular Detection of Rickettsia in American Dog Ticks Collected Along the Platte River in South Central Nebraska Brandon Luedtke1, Julie Shaffer1, Estrella Monrroy1, Corey Willicott1, Travis Bourret2 1University of Nebraska-Kearney, Kearney, USA. 2Creighton University School of Medicine, Omaha, USA Abstract Dermacentor variabilis is the predominant tick species in Nebraska and is presumed to be the primary vector of Rickettsia rickettsii associated with Nebraskans that have contracted Rocky Mountain spotted fever. Interestingly, cases of Rocky Mountain spotted fever in Nebraska have increased on a year over year basis, yet the prevalence of D. variabilis vectoring R. rickettsii has not been established for Nebraska. Here we sought to set a baseline for the prevalence of D. variabilis vectoring R. rickettsii and other spotted fever group (SFG) rickettsiae. Over a 3 year period, D. variabilis were collected along the Platte River in south central Nebraska. Individual tick DNA was analyzed using endpoint PCR to identify ticks carrying SFG rickettsiae. A total of 927 D. variabilis were analyzed by PCR and 38 (4.1%) ticks tested positive for SFG rickettsiae. Presumptive positives were sequenced to identify the Rickettsia species, of which 29 (76%) were R. montanensis, 5 (13%) were R. amblyommatis, 4 (11%) were R. bellii, and R. rickettsii was not detected. These data indicate that R. rickettsii is likely at a low prevalence in south central Nebraska and spillover of R. amblyommatis into D. variabilis is occurring likely due to the invasive lone star tick (Amblyoma americanum).
    [Show full text]
  • November 2014, Version 6.0 This Document Was Created Under National Center for Emerging and Zoonotic Diseases/ Office of Infectious Diseases (NCEZID/OD)
    November 2014, Version 6.0 This document was created under National Center for Emerging and Zoonotic Diseases/ Office of Infectious Diseases (NCEZID/OD). The printed version of CDC's Infectious Diseases Laboratory Test Directory contains information that is current as of November 18st, 2014. All information contained herein is subject to change. For the most current test information, please view the CDC's Infectious Diseases Laboratory Test Directory on: http://www.cdc.gov/laboratory/specimen-submission/list.html. Test Order Acanthamoeba Molecular Detection CDC-10471 Synonym(s) Free-living ameba, parasite Pre-Approval Needed None Supplemental Information None Required Supplemental Form None Performed on Specimens From Human Acceptable Sample/ Specimen For Acanthamoeba and Balamuthia molecular detection, tissue is the preferred Type for Testing specimen type; however, these amoebae can occasionally be detected in cerebrospinal fluid (CSF). For Naegleria fowleri molecular detection, CSF is the preferred specimen type. Minimum Volume Required 500 uL Storage & Preservation of Storage and preservation is specimen specific Specimen Prior to Shipping Transport Medium Not Applicable Specimen Labeling Test subject to CLIA regulations and requires two patient identifiers on the specimen container and the test requisition. In addition to two patient identifiers (sex, date of birth, name, etc.), provide specimen type and date of collection. Shipping Instructions which Ship Monday – Thursday, overnight to avoid weekend deliveries. Ship specimen Include
    [Show full text]
  • Antimicrobial Susceptibilities of Selected Pathogens, 1999
    ✔ Antimicrobial Susceptibilities * * † 7 of Selected Pathogens, 1999 8 e † a 2 ✔ ✔ † 3 ✔ † 4 5 6 culosis * r 1 urium spp. m L spp. Sampling Methodology 2 L † all isolates tested * ~ 20% sample of statewide isolates received at MDH spp. ~10% sample of statewide isolates received at MDH Salmonella ** all isolates tested from 7-county metropolitan area oup A streptococci ✔ oup B streptococci r isolates from a normally sterile site r Other (non-typhoidal) G Campylobacter Salmonella typhi Shigella Neisseria gonorrhoeae Neisseria meningitidis G Streptococcus pneumoni Mycobacterium tube No. of Isolates Tested 131 160 43 20 250 55 162 192 559 163 123456 123456% Susceptib123456le 123456123456 123456 123451623456 123451623456 ampicillin 1234561234566012345686 123456 15123456123456 100 100 123456123456 123451623451623451623451623456 123456 penicillin 123456123456123456123456123456 98100 100 76 123456 123456123456123456123456123456123456123456123456 123456 123451623451623451623456 123451623451623456 123456 cefuroxime sodium 123456123456123456123456 100123456123456123456 81 123456 123456123456123456123456123456123456123456123456 123456 cefotaxime 123451623451623451623451623456 100 100100 83 123456 123456123456123456123456123456 123456123456123456123456 123456 123456123456123456123456 ceftriaxone 123456 100 95 100 100 100 123451623451623451623456 -lactam antibiotics 123456123456123456123456123456 123456123456123456123456 β 123451623451623451623451623456 123451623456 123456 meropenem 123456123456123456123456123456 100 123456123456 83 123456 123456123456123456123456123456123456123456123456
    [Show full text]
  • Microbial NAD Metabolism: Lessons from Comparative Genomics
    Dartmouth College Dartmouth Digital Commons Dartmouth Scholarship Faculty Work 9-2009 Microbial NAD Metabolism: Lessons from Comparative Genomics Francesca Gazzaniga Rebecca Stebbins Sheila Z. Chang Mark A. McPeek Dartmouth College Charles Brenner Carver College of Medicine Follow this and additional works at: https://digitalcommons.dartmouth.edu/facoa Part of the Biochemistry Commons, Genetics and Genomics Commons, Medicine and Health Sciences Commons, and the Microbiology Commons Dartmouth Digital Commons Citation Gazzaniga, Francesca; Stebbins, Rebecca; Chang, Sheila Z.; McPeek, Mark A.; and Brenner, Charles, "Microbial NAD Metabolism: Lessons from Comparative Genomics" (2009). Dartmouth Scholarship. 1191. https://digitalcommons.dartmouth.edu/facoa/1191 This Article is brought to you for free and open access by the Faculty Work at Dartmouth Digital Commons. It has been accepted for inclusion in Dartmouth Scholarship by an authorized administrator of Dartmouth Digital Commons. For more information, please contact [email protected]. MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, Sept. 2009, p. 529–541 Vol. 73, No. 3 1092-2172/09/$08.00ϩ0 doi:10.1128/MMBR.00042-08 Copyright © 2009, American Society for Microbiology. All Rights Reserved. Microbial NAD Metabolism: Lessons from Comparative Genomics Francesca Gazzaniga,1,2 Rebecca Stebbins,1,2 Sheila Z. Chang,1,2 Mark A. McPeek,2 and Charles Brenner1,3* Departments of Genetics and Biochemistry and Norris Cotton Cancer Center, Dartmouth Medical School, Lebanon, New Hampshire
    [Show full text]
  • Plesiomonas Shigelloides S000142446 Serratia Plymuthica
    0.01 Plesiomonas shigelloides S000142446 Serratia plymuthica S000016955 Serratia ficaria S000010445 Serratia entomophila S000015406 Leads to highlighted edge in Supplemental Phylogeny 1 Xenorhabdus hominickii S000735562 0.904 Xenorhabdus poinarii S000413914 0.998 0.868 Xenorhabdus griffiniae S000735553 Proteus myxofaciens S000728630 0.862 Proteus vulgaris S000004373 Proteus mirabilis S000728627 0.990 0.822 Arsenophonus nasoniae S000404964 OTU from Corby-Harris (Unpublished) #seqs-1 GQ988429 OTU from Corby-Harris et al (2007) #seqs-1 DQ980880 0.838 Providencia stuartii S000001277 Providencia rettgeri S000544654 0.999 Providencia vermicola S000544657 0.980 Isolate from Juneja and Lazzaro (2009)-EU587107 Isolate from Juneja and Lazzaro (2009)-EU587113 0.605 0.928 Isolate from Juneja and Lazzaro (2009)-EU587095 0.588 Isolate from Juneja and Lazzaro (2009)-EU587101 Providencia rustigianii S000544651 0.575 Providencia alcalifaciens S000127327 0.962 OTU XDS 099-#libs(1/0)-#seqs(1/0) OTU XYM 085-#libs(13/4)-#seqs(401/23) 0.620 OTU XDY 021-#libs(1/1)-#seqs(3/1) Providencia heimbachae S000544652 Morganella psychrotolerans S000721631 0.994 Morganella morganii S000721642 OTU ICF 062-#libs(0/1)-#seqs(0/7) Morganella morganii S000129416 0.990 Biostraticola tofi S000901778 0.783 Sodalis glossinidius S000436949 Dickeya dadantii S000570097 0.869 0.907 0.526 Brenneria rubrifaciens S000022162 0.229 Brenneria salicis S000381181 0.806 OTU SEC 066-#libs(0/1)-#seqs(0/1) Brenneria quercina S000005099 0.995 Pragia fontium S000022757 Budvicia aquatica S000020702
    [Show full text]
  • The Old Testament Is Dying a Diagnosis and Recommended Treatment 1St Edition Download Free
    THE OLD TESTAMENT IS DYING A DIAGNOSIS AND RECOMMENDED TREATMENT 1ST EDITION DOWNLOAD FREE Brent A Strawn | 9780801048883 | | | | | David T. Lamb Strawn offers a few other concrete suggestions about how to save the Old Testament, illustrating several of these by looking at the book of Deuteronomy as a model for second language acquisition. Retrieved 27 August The United States' Centers for Disease Control and Prevention CDC currently recommend that individuals who have been diagnosed and treated for gonorrhea avoid sexual contact with others until at least one week past the final day of treatment in order to prevent the spread of the bacterium. Brent Strawn reminds us of the Old Testament's important role in Christian faith and practice, criticizes current misunderstandings that contribute to its neglect, and offers ways to revitalize its use in the church. None, burning with urinationvaginal dischargedischarge from the penispelvic paintesticular pain [1]. Stunted language learners either: leave faith behind altogether; remain Christian, but look to other resources for how to live their lives; or balkanize in communities that prefer to speak something akin to baby talk — a pidgin-like form of the Old Testament and Bible as a whole — or, worse still, some sort of creole. Geoff, thanks for the reference. Log in. The guest easily identified the passage The Old Testament Is Dying A Diagnosis and Recommended Treatment 1st edition the New Testament, but the Old Testament passage was a swing, and a miss. Instead, our system considers things like how recent a review is and if the reviewer bought the item on Amazon.
    [Show full text]
  • 2017 VBDS Annual Report
    Vector-Borne Disease Section Annual Report 2017 Infectious Diseases Branch Division of Communicable Disease Control Center for Infectious Diseases California Department of Public Health 2017 ANNUAL REPORT VECTOR-BORNE DISEASE SECTION INFECTIOUS DISEASES BRANCH DIVISION OF COMMUNICABLE DISEASE CONTROL CENTER FOR INFECTIOUS DISEASES CALIFORNIA DEPARTMENT OF PUBLIC HEALTH Edmund G. Brown Jr. Governor State of California Michael Wilkening, Secretary Karen Smith, MD, MPH, Director Health and Human Services Agency Department of Public Health VBDS Annual Report, 2017 Contents Preface.......................................................................................................................................................................................................iii Acknowledgements ............................................................................................................................................................................ iv Suggested Citations ............................................................................................................................................................................ vi Program Overview.............................................................................................................................................................................. vii Chapters 1 Rodent-borne Diseases 1 2 Flea-borne Diseases 4 3 Tick-borne Diseases 7 4 Mosquito-borne Diseases 13 5 U.S. Forest Service Cost-Share Agreement 21 6 Vector Control Technician Certifcation
    [Show full text]
  • Comparative Microbiome Profiles of Sympatric Tick Species from the Far
    insects Article Comparative Microbiome Profiles of Sympatric Tick Species from the Far-Western United States Betsabel Chicana 1, Lisa I. Couper 2, Jessica Y. Kwan 3 , Enxhi Tahiraj 4 and Andrea Swei 4,* 1 Quantitative and Systems Biology Program, University of California, Merced, CA 95343, USA; [email protected] 2 Department of Biology, Stanford University, Palo Alto, CA 94305, USA; [email protected] 3 School of Veterinary Medicine, University of California, Davis, CA 95616, USA; [email protected] 4 Department of Biology, San Francisco State University, 1600 Holloway Ave, San Francisco, CA 94132, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-(415)-338-1753 Received: 2 September 2019; Accepted: 11 October 2019; Published: 18 October 2019 Abstract: Insight into the composition and function of the tick microbiome has expanded considerably in recent years. Thus far, tick microbiome studies have focused on species and life stages that are responsible for transmitting disease. In this study we conducted extensive field sampling of six tick species in the far-western United States to comparatively examine the microbial composition of sympatric tick species: Ixodes pacificus, Ixodes angustus, Dermacentor variabilis, Dermacentor occidentalis, Dermacentor albipictus, and Haemaphysalis leporispalustris. These species represent both common vectors of disease and species that rarely encounter humans, exhibiting a range of host preferences and natural history. We found significant differences in microbial species diversity and composition by tick species and life stage. The microbiome of most species examined were dominated by a few primary endosymbionts. Across all species, the relative abundance of these endosymbionts increased with life stage while species richness and diversity decreased with development.
    [Show full text]